Angelo Gousse, MD
Urology · Miramar, FLNPI 1821028259
Payments from drug & device makers
Across 206 payments — averaging $575.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$66K
- AbbVie$32K
- Ferring Pharmaceuticals Inc.$12K
- Ipsen Innovation$4K
- Coloplast$2K
- Axonics, Inc.$841
- plus $2K from 29 others
What the payments were for
- Consulting fees$9,19129%
- Speaking & faculty fees$13,35041%
- Travel & lodging$4,94315%
- Food & beverage$4,28613%
- Education$4301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 5 | $65,783 |
| AbbVie(2 entities) | 32 | $31,611 |
| Ferring Pharmaceuticals Inc. | 20 | $12,204 |
| Ipsen Innovation | 1 | $4,000 |
| Coloplast | 40 | $1,609 |
| Axonics, Inc. | 20 | $841 |
| Boston Scientific | 12 | $555 |
| Astellas Pharma US Inc | 20 | $372 |
| Kerecis Limited | 1 | $171 |
| Laborie Medical Technologies Corp. | 3 | $164 |
| Rochester Medical Corporation | 5 | $155 |
| Myriad Genetic Laboratories, Inc. | 4 | $129 |
| C. R. Bard, Inc. & Subsidiaries | 5 | $113 |
| Endo Pharmaceuticals Inc. | 6 | $107 |
| Medtronic | 3 | $75 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Convatec Inc. | 2 | $56 |
| Mission Pharmacal Company | 3 | $54 |
| Tolmar, Inc. | 2 | $43 |
| Verity Pharmaceuticals Inc. | 2 | $42 |
| Biosense Webster, Inc. | 1 | $40 |
| Tolmar Pharmaceuticals, Inc. | 2 | $39 |
| Myovant Sciences Inc. | 2 | $32 |
| AstraZeneca | 1 | $25 |
| Bard Access Systems, Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Angiodynamics, Inc. | 1 | $20 |
| Blue Earth Diagnostics | 1 | $19 |
| Aytu Biopharma, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Olympus America Inc. | 1 | $17 |
| Valencia Technologies Corporation | 1 | $15 |
| Urovant Sciences Inc | 1 | $15 |
| Procept Biorobotics Corporation | 1 | $14 |
| Rigicon,inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$14,899
- NOCDURNA$11,869
- TITAN$1,169
- Kerecis Omega3 SurgiClose$514
- Bulkamid$489
- Axonics r-SNM System$489
- Kerecis Omega3 GraftGuide$171
- Kerecis Omega3 Marigen$171
- Optilume BPH Drug Coated Balloon Catheter$120
How this compares
$118,481 in reported general payments places this provider in the 90th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 269 | $139,372 |
| TrelstarTriptorelin Pamoate | 31 | $76,598 |
| GemtesaVibegron | 29 | $18,589 |
| Tadalafil | 104 | $10,605 |
| Solifenacin Succinate | 151 | $7,978 |
| Tamsulosin Hcl | 492 | $3,422 |
| Methenamine Hippurate | 43 | $2,745 |
| Sildenafil Citrate | 164 | $1,853 |
| Ciprofloxacin Hcl | 245 | $1,248 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 96 | $766 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 74 | $760 |
| Doxazosin Mesylate | 48 | $495 |
| Oxybutynin Chloride ErOxybutynin Chloride | 35 | $453 |
| Cephalexin | 20 | $444 |
| Finasteride | 44 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $372 | $139,372269 claims |
| Verity Pharmaceuticals Inc.Trelstar | $42 | $76,59831 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $71 | $18,58929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 urology providers in Florida.
Other urology in Miramar
- Steven KesterPompano Beach$5.7M
- Harvey SamowitzHallandale Beach$3.6M
- Paul PeritoCoral Gables$3.6M
- Graham GreeneLakeland$2.5M
- Scott SellingerTallahassee$2.3M
- Fernando BiancoHialeah$2.2M
- Osvaldo PadronTampa$1.3M
- Mark Anthony GonzalgoMiami$1.1M
- Paul CrispenGainesville$1.1M
- Craig HermanPompano Beach$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.